Reinitiating Chemotherapy beyond Progression after Maintenance Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

<i>Introduction</i>: Small-cell lung cancer (SCLC) is an aggressive form of cancer with a poor prognosis. The two-year survival rate is 8% of all cases. <i>Case presentation</i>: We present the case of a male patient who was 50 years old at the time of diagnosis in May 2022....

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Medicina
المؤلفون الرئيسيون:	Roxana-Andreea Rahnea-Nita, Radu-Valeriu Toma, Valentin Titus Grigorean, Ionuţ Simion Coman, Violeta Elena Coman, Iancu Emil Pleşea, Anwar Erchid, Gabriel-Petre Gorecki, Gabriela Rahnea-Nita
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2024-07-01
الموضوعات:	small-cell lung cancer first-line immunotherapy reinitiating chemotherapy Epoetinum alpha
الوصول للمادة أونلاين:	https://www.mdpi.com/1648-9144/60/8/1225